Drug
Neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
recruiting267%
terminated133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
NCT07483307
recruitingphase_2
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT06806930
terminatedphase_3
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
NCT02532400
Clinical Trials (3)
Showing 3 of 3 trials
NCT07483307Phase 2
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
NCT06806930Phase 2
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT02532400Phase 3
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3